Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?

Real-World Management of HMA-Related Myelosuppression During MDS Treatment in the Canadian Landscape.

Current oncology (Toronto, Ont.)·2026

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026

Luspatercept in myelodysplastic syndrome with ring sideroblasts: a case report of intrapulmonary vascular dilatation syndrome causing protracted inexplicable hypoxia.

Haematologica·2026

Initial leukemic epigenomic state determines hypomethylating agent response.

Nature communications·2026

Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysis.

Intensive care medicine·2026

Management of iron overload in adult myelodysplastic syndrome.

Hematology. American Society of Hematology. Education Program·2025

High time for risk-adapted treatment in mantle cell lymphoma.

The Lancet. Haematology·2026

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

The Lancet. Haematology·2026

Beyond maximum grade: key regulatory considerations in adverse event reporting.

The Lancet. Haematology·2026

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

The Lancet. Haematology·2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology·2026

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

The Lancet. Haematology·2026

How Much Dissection Is Enough? Mesenteric Vessel Skeletonization Length and Lymph Node Harvest Quality in Rectal Cancer Surgery.

The American surgeon·2026

Follicular lymphoma and the microenvironment: potential targets and biomarkers.

Expert review of clinical immunology·2026

Histotripsy for Hepatocellular Carcinoma: From Bench to Bedside.

Radiology·2026

Targeting the HEC1-NEK2 Axis Suppresses DLBCL Progression and Overcomes Vincristine Resistance.

Molecular cancer therapeutics·2026

KSHV promotes leukocyte adhesion and transendothelial migration via induction of VCAM1.

mBio·2026

Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling.

Cancer reports (Hoboken, N.J.)·2026

Related Experiment Videos

Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?

Related Concept Videos

Real-World Management of HMA-Related Myelosuppression During MDS Treatment in the Canadian Landscape.

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Luspatercept in myelodysplastic syndrome with ring sideroblasts: a case report of intrapulmonary vascular dilatation syndrome causing protracted inexplicable hypoxia.

Initial leukemic epigenomic state determines hypomethylating agent response.

Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysis.

Management of iron overload in adult myelodysplastic syndrome.

High time for risk-adapted treatment in mantle cell lymphoma.

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

Beyond maximum grade: key regulatory considerations in adverse event reporting.

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.

How Much Dissection Is Enough? Mesenteric Vessel Skeletonization Length and Lymph Node Harvest Quality in Rectal Cancer Surgery.

Follicular lymphoma and the microenvironment: potential targets and biomarkers.

Histotripsy for Hepatocellular Carcinoma: From Bench to Bedside.

Targeting the HEC1-NEK2 Axis Suppresses DLBCL Progression and Overcomes Vincristine Resistance.

KSHV promotes leukocyte adhesion and transendothelial migration via induction of VCAM1.

Bufalin Inhibits Melanoma Progression and Endothelial Angiogenic Phenotypes via AKT Signaling.

Related Experiment Videos

Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?

Related Concept Videos

Related Articles